TJU is currently recruiting patients for Rituximab Treatment of SSc-PAH
ASCO1 Study
ASC01: Rituximab for Treatment of SSc-PAH
Sponsored by the National Institutes of Health (NIH) through its Division of Allergy, Immunology, & Transplantation (DAIT) of the National Institute of Allergy & Infectious Disease (NIAID)
Conducted by Dr. Sandra Weibel
Thomas Jefferson University
Tele: 215-955-6591 Email: Sandra.Weibel@jefferson.edu
We are looking for patients who …
· have systemic sclerosis (scleroderma)
· have pulmonary arterial hypertension (PAH) which
~ is not due to pulmonary fibrosis &
~ has been diagnosed less than 5 years ago
· have been on stable PAH treatment (prostanoid &/or endothelin receptor antagonist &/or PDE-5 inhibitor) for the last 3 months
· are 18-75 years old
Primary Hypothesis: rituximab-treated subjects will demonstrate improvement or stabilization compared to the placebo-treated subjects in pulmonary vascular resistance from baseline to 24 weeks post-treatment.
|
Screening by Clinical Trial Site
|
|
Rituximab plus Standard Therapy
|
|
Placebo plus Standard Therapy
|
|
Monthly Follow-Up Visits for One Year
|
Study Design:
Published: 11-23-2011